Drug
Obrixtamig
Obrixtamig: highest development phase Phase 3, developed by Boehringer Ingelheim. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| obrixtamig NCT07472517 | Phase 3 | Small Cell Lung Cancer (SCLC) |
| Obrixtamig NCT07544654 | Phase 3 | Extrapulmonary Neuroendocrine Cancer (epNEC) |
| Obrixtamig NCT07929051 | Phase 3 | Advanced Cancer |
| Obrixtamig NCT07707895 | Phase 1/2 | Small Cell Lung Cancer |
| Obrixtamig NCT07843940 | Phase 1/2 | Extensive-stage Small Cell Lung Carcinoma |
Latest
Follow Obrixtamig on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.